CN112888437A - 加波沙朵在治疗胃肠道紊乱和哮喘中的用途 - Google Patents

加波沙朵在治疗胃肠道紊乱和哮喘中的用途 Download PDF

Info

Publication number
CN112888437A
CN112888437A CN201980069028.1A CN201980069028A CN112888437A CN 112888437 A CN112888437 A CN 112888437A CN 201980069028 A CN201980069028 A CN 201980069028A CN 112888437 A CN112888437 A CN 112888437A
Authority
CN
China
Prior art keywords
hours
patient
gaboxadol
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980069028.1A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN112888437A publication Critical patent/CN112888437A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980069028.1A 2018-08-22 2019-08-22 加波沙朵在治疗胃肠道紊乱和哮喘中的用途 Pending CN112888437A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721013P 2018-08-22 2018-08-22
US62/721,013 2018-08-22
PCT/US2019/047673 WO2020041574A1 (en) 2018-08-22 2019-08-22 Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma

Publications (1)

Publication Number Publication Date
CN112888437A true CN112888437A (zh) 2021-06-01

Family

ID=69591079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980069028.1A Pending CN112888437A (zh) 2018-08-22 2019-08-22 加波沙朵在治疗胃肠道紊乱和哮喘中的用途

Country Status (10)

Country Link
US (1) US20210177805A1 (enExample)
EP (1) EP3823619A4 (enExample)
JP (1) JP2021535106A (enExample)
KR (1) KR20210049855A (enExample)
CN (1) CN112888437A (enExample)
AU (1) AU2019326539A1 (enExample)
CA (1) CA3110218A1 (enExample)
IL (1) IL280859A (enExample)
MX (1) MX2021002113A (enExample)
WO (1) WO2020041574A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN115551514A (zh) * 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974351A2 (en) * 1998-04-24 2000-01-26 Jouveinal Medicament for preventing and treating gastrointestinal damage
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4307800A (en) * 1999-04-30 2000-11-17 Merab Lomia New indication for use of antiepileptic agents and medicines
EP1863808A1 (en) * 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974351A2 (en) * 1998-04-24 2000-01-26 Jouveinal Medicament for preventing and treating gastrointestinal damage
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEORGE GALLOS，ET AL.: "Targeting the restricted α-subunit repertoire of airway smooth muscle GABAA receptors augments airway smooth muscle relaxation", AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 302, pages 248 - 256 *
MOHSEN SEIFI,ET AL.: "GABAA Receptor Subtypes Regulate Stress-Induced Colon Inflammation in Mice", GASTROENTEROLOGY, vol. 155, pages 852 - 864 *

Also Published As

Publication number Publication date
CA3110218A1 (en) 2020-02-27
EP3823619A4 (en) 2021-11-17
IL280859A (en) 2021-04-29
WO2020041574A1 (en) 2020-02-27
EP3823619A1 (en) 2021-05-26
JP2021535106A (ja) 2021-12-16
US20210177805A1 (en) 2021-06-17
AU2019326539A1 (en) 2021-03-11
KR20210049855A (ko) 2021-05-06
MX2021002113A (es) 2021-06-23

Similar Documents

Publication Publication Date Title
US20090252708A1 (en) Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
CA3070453A1 (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
Kathani Amin et al. Common and alternate oral antibiotic therapies for acne vulgaris: a review
WO2008073517A1 (en) Treatment for intestinal gas, bloating, microscopic colitis and traveler's diarrhea using colloidal bismuth subcitrate
CN111971035A (zh) 生酮饮食相容的芬氟拉明制剂
AU2017253087A1 (en) Compositions and methods for improved restoration and preservation of the integrity of tissue barriers
EP2968309A2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
CA2821196A1 (en) Gastric and colonic formulations and methods for making and using them
WO2011028794A2 (en) Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
CN116390712A (zh) 治疗偏头痛
BR112021009365A2 (pt) formulação de glicocorticoide estável
Othman et al. Combined ketamine and midazolam versus midazolam alone for initial treatment of pediatric generalized convulsive status epilepticus (Ket-Mid Study): a randomized controlled trial
EP2338495A1 (en) Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease
US20210177805A1 (en) Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
CA3251932A1 (en) COMBINATION OF TAURURSODIOL AND SODIUM PHENYLBUTYRATE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
CN104394691A (zh) 用5-氨基水杨酸治疗过敏性肠道综合症的组合物和方法
TW201803558A (zh) 腸內環境改善劑
KR20210087952A (ko) 운동 장애들을 치료하기 위한 가복사돌, 가낙솔론 및 알로프레그나놀론의 사용
Danziger et al. Beta-lactam antibiotics
CN112930182A (zh) 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
US20080159987A1 (en) Use of Rifaximin for the Treatment of Restless Legs Syndrome
Kaji et al. A side effect of neuraminidase inhibitor in a patient with liver cirrhosis
CN120641088A (zh) (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸用于胃肠道紊乱和作为免疫调节剂的用途
WO2005055997A1 (ja) 炎症性疾患の治療及び予防用医薬組成物
US11690829B2 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210601

WD01 Invention patent application deemed withdrawn after publication